Compound Detail
CHEMBL12713
SERTINDOLE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL12713 |
| Name | SERTINDOLE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | GZKLJWGUPQBVJQ-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
29
Targets
76
Activities
2
Assay Types
3
PK Parameters
20
Publications
7
Known Names
6
Indications
3
Mechanisms
Molecular Properties
440.9
MW (Da)
4.63
ALogP
3
HBA
1
HBD
40.5
PSA (Ų)
0.63
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1996 |
| Availability | Withdrawn |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Dopamine D2 receptor antagonist | ANTAGONIST | D(2) dopamine receptor | ✓ | ✓ |
| Adrenergic receptor alpha-1 antagonist | ANTAGONIST | Adrenergic receptor alpha-1 | ✓ | ✓ |
| Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist | ANTAGONIST | Serotonin 2 receptors; 5-HT2a & 5-HT2c | ✓ | ✓ |
Indications
Psychotic Disorders Anxiety Cognitive Dysfunction Dementia Depressive Disorder Schizophrenia
ATC Classification
N05AE03
sertindole
Level 1: NERVOUS SYSTEM
Level 2: PSYCHOLEPTICS
Drug Warnings
Withdrawn
cardiotoxicity
Arrhythmias and Sudden Cardiac Death (Arrhythmias and Sudden)
Withdrawn
cardiotoxicity
Arrhythmias and Sudden Cardiac Death (Arrhythmias and Sudden)
Withdrawn
General Warning
serious adverse reactions
Activity Summary
IC50 41 meas. best 9.41
Ki 35 meas. best 9.7
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2C CHEMBL225 | Ki | 9.7 | 9.1967 | 0.2 | 3 |
| 5-hydroxytryptamine receptor 2A CHEMBL322 | Ki | 9.7 | 9.7 | 0.2 | 1 |
| Alpha-1B adrenergic receptor CHEMBL3122 | Ki | 9.48 | 9.48 | 0.3 | 3 |
| Alpha-1A adrenergic receptor CHEMBL4892 | Ki | 9.43 | 9.43 | 0.4 | 3 |
| D(2) dopamine receptor CHEMBL217 | Ki | 9.42 | 9.0625 | 0.4 | 4 |
| Serotonin 2 (5-HT2) receptor CHEMBL2093870 | IC50 | 9.41 | 9.3875 | 0.4 | 4 |
| 5-hydroxytryptamine receptor 2A CHEMBL322 | IC50 | 9.41 | 9.41 | 0.4 | 1 |
| D(2) dopamine receptor CHEMBL339 | Ki | 9.35 | 9.35 | 0.5 | 1 |
| 5-hydroxytryptamine receptor 2C CHEMBL324 | Ki | 9.29 | 9.29 | 0.5 | 1 |
| Histamine H1 receptor CHEMBL231 | Ki | 9.29 | 7.765 | 0.5 | 2 |
| 5-hydroxytryptamine receptor 2A CHEMBL224 | Ki | 9.22 | 9.145 | 0.6 | 2 |
| Alpha-1D adrenergic receptor CHEMBL326 | Ki | 9.18 | 9.18 | 0.7 | 3 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | Ki | 8.85 | 8.85 | 1.4 | 1 |
| Adrenergic receptor alpha-1 CHEMBL2094251 | Ki | 8.74 | 8.74 | 1.8 | 1 |
| D(3) dopamine receptor CHEMBL234 | Ki | 8.59 | 8.34 | 2.6 | 2 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 8.57 | 8.025 | 2.7 | 14 |
| Alpha-1A adrenergic receptor CHEMBL319 | IC50 | 8.47 | 8.47 | 3.4 | 2 |
| Adrenergic receptor alpha-1 CHEMBL1907610 | IC50 | 8.47 | 8.47 | 3.4 | 1 |
| D(2) dopamine receptor CHEMBL339 | IC50 | 8.39 | 8.39 | 4.1 | 5 |
| 5-hydroxytryptamine receptor 6 CHEMBL3371 | Ki | 8.3 | 8.3 | 5.0 | 1 |
| D(4) dopamine receptor CHEMBL219 | Ki | 7.96 | 7.82 | 11.0 | 2 |
| D(1A) dopamine receptor CHEMBL265 | Ki | 7.92 | 7.92 | 12.0 | 1 |
| 5-hydroxytryptamine receptor 1A CHEMBL214 | Ki | 7.48 | 7.48 | 33.0 | 1 |
| 5-hydroxytryptamine receptor 1B CHEMBL1898 | Ki | 7.25 | 7.25 | 56.0 | 1 |
| D(1A) dopamine receptor CHEMBL2056 | Ki | 6.68 | 6.68 | 210.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 5.85 | 5.54 | 1425.2 | 8 |
| Adrenergic receptor alpha-2 CHEMBL2095158 | Ki | 5.78 | 5.78 | 1680.0 | 1 |
| Potassium voltage-gated channel subfamily A member 5 CHEMBL4306 | IC50 | 5.7 | 5.7 | 2000.0 | 1 |
| Sodium channel alpha subunit CHEMBL2331043 | IC50 | 5.64 | 5.64 | 2300.0 | 1 |
| Voltage-gated L-type calcium channel CHEMBL2095229 | IC50 | 5.2 | 5.125 | 6300.0 | 2 |
| ATP-dependent translocase ABCB1 CHEMBL4302 | IC50 | 5.19 | 5.19 | 6500.0 | 1 |
| Bile salt export pump CHEMBL6020 | IC50 | 4.08 | 4.08 | 82700.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| F | 75.0 | % | Homo sapiens |
| T1/2 | 53.0 | hr | Rattus norvegicus |
| Vd | 20.0 | L.kg-1 | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| 1336054 | 10.1021/jm00104a007 | Rattus norvegicus | 4 |
| 1336053 | 10.1021/jm00104a006 | Rattus norvegicus | 4 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| 8809161 | 10.1021/jm960159f | Rattus norvegicus | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2A | 3 |
| 1348090 | 10.1021/jm00084a014 | D(2) dopamine receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 2B | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 3 |
| 38516587 | 10.1039/d3md00677h | ADMET | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Alpha-1A adrenergic receptor | 3 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Voltage-dependent L-type calcium channel subunit alpha-1C | 2 |
| 19534531 | 10.1021/jm900002x | Voltage-gated inwardly rectifying potassium channel KCNH2 | 2 |
| 1348090 | 10.1021/jm00084a014 | Rattus norvegicus | 2 |
| 11356099 | 10.1021/jm000484+ | Voltage-gated inwardly rectifying potassium channel KCNH2 | 2 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 2 |
| 1336053 | 10.1021/jm00104a006 | Mus musculus | 2 |
Data from ChEMBL 36 via Core Engine